Abstracts tagged "autoimmune diseases"

Abstract Number: 2033 • 2019 ACR/ARP Annual Meeting
IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Angie Hammond¹, Sean Parghi ¹, Nathan Wright ¹, Ethan Grant ¹, James Taylor ¹ and Matthew Warr ¹, ¹Gilead Sciences, Inc., Foster City, CA
Background/Purpose: A hallmark of lupus is the presence of antinuclear autoantibodies, including those against RNA-protein complexes and double-stranded DNA (dsDNA).1,2 FcγR-mediated internalization of these nucleic…
Abstract Number: 712 • 2019 ACR/ARP Annual Meeting
Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Oliver Distler¹, Kristin Highland ², Maureen Mayes ³, Masataka Kuwana ⁴, Lesley Saketkoo ⁵, Madelon Vonk ⁶, Michael Kreuter ⁷, Laura Hummers ⁸, Ute von Wangenheim ⁹, Martina Gahlemann ¹⁰, Veronika Kohlbrenner ¹¹, Margarida Alves ¹², Emmanuelle Clerisme-Beaty ¹² and Arata Azuma ¹³, ¹Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁶Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, ¹⁰Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹¹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), the adverse events associated with nintedanib were manageable for most patients…
Abstract Number: 2075 • 2019 ACR/ARP Annual Meeting
Cross-sectional Study and Mendelian Randomization Analysis of Diet in Six Prevalent Autoimmune Diseases
Antonio Julià¹, Sergio H Martinez ², Jesús Tornero ³, Juan Cañete ⁴, Antonio Fernández-Nebro ⁵, Francisco J. Blanco ⁶, Jesús Rodríguez ⁷, Francisco Javier Lopez-Longo ⁸, Benjamín Fernandez-Gutierrez ⁹, Jordi Gratacós ¹⁰, Jose J Pérez Venegas ¹¹, Carolina Pérez ¹², Ruben Queiró ¹³, Alejandro Olivé-Marqués ¹⁴, Mercedes Alperi-López ¹⁵, Carlos Montilla ¹⁶, José Luís Andreu ¹⁷, Juan Carlos Torre-Alonso ¹⁸, Mª Ángeles Aguirre-Zamorano ¹⁹, Hèctor Corominas ²⁰, Paloma Vela ²¹, Víctor Martínez-Taboada ²², Sara Marique ²³, Joan M Nolla ²⁴, Isidoro Gonzalez ²⁵, Santiago Muñoz-Fernandez ²⁶, José Luís Marenco de la Fuente ²⁷, Carlos González ²⁸, Antonio Zea ²⁹, Maria Lopez Lasanta ³⁰, Daniel Roig ³¹, Jose Maria Pego-Reigosa ³², Mireia Lopez Corbeto ³³, Pedro Zarco ³⁴, Mercedes Freire González ³⁵, Alba Erra ³⁶, Elvira Díez ³⁷, Santos Castañeda ³⁸, Esther Rodriguez ³⁹, Alicia García ⁴⁰, Patricia Carreira ³⁹, Georgina Salvador ⁴¹, Ricardo Blanco ⁴², Cesar Diaz-Torne ⁴³, Alfredo Willisch Domínguez ⁴⁴, Joan Antonio Mosquera ⁴⁵, Simón Sánchez-Fernández ⁴⁶, Júlio Ramírez ⁴⁷ and Sara Marsal ⁴⁸, ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ³Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁴Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁵Hospital Carlos Haya, Malaga, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ⁷Hospital Universitario de Bellvitge, Hospitalet, Spain, ⁸Hospital Universitario Gregorio Marañón, Madrid, Madrid, Spain, ⁹Hospital Clínico San Carlos, Madrid, Madrid, Spain, ¹⁰Hospital Parc Taulí, Sabadell, Catalonia, Spain, ¹¹Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ¹²Parc de Salut Mar, Barcelona, Barcelona, Spain, ¹³Hospital Universitario Central de Asturias, Oviedo, Oviedo, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁷Hospital Puerta de Hierro, Madrid, Madrid, Spain, ¹⁸Hospital Monte Naranco, Oviedo, Spain, ¹⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain, ²¹Hospital General Universitario de Alicante, Alicante, Spain, ²²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²³Hospital Regional Univeristario de Málaga, Málaga, Spain, ²⁴Hospital Universitari de Bellvitge, Hospitalet, Spain, ²⁵Hospital Universitario La Princesa, Madrid, Spain, ²⁶Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ²⁷Hospital Valme, Sevilla, Sevilla, Spain, ²⁸Hospital Universitario Gregorio Marañón, Madrid, Spain, ²⁹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³⁰Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³¹Hospital Moisès Broggi, Barcelona, Sant Joan Despí, Barcelona, Singapore, ³²Complexo Hospitalario Universitario, Vigo, Spain, ³³Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ³⁴Hospital Universitario Fundación Alcorcón, Madrid, Madrid, Spain, ³⁵Hospital Universitario Juan Canalejo, La Coruña, Spain, ³⁶H Sant Rafael, Barcelona, Barcelona, Spain, ³⁷Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ³⁸Rheumatology, Hospital Universitario La Princesa, Madrid, Madrid, Spain, ³⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁰Centro de Salud Virgen de los Reyes, Sevilla, Sevilla, Spain, ⁴¹Hospital Mútua Terrassa, Terrassa, Spain, ⁴²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴³Hospital de la Santa Creu i Sant Pau, barcelona, Catalonia, Spain, ⁴⁴Complexo Hospitalario de Ourense, Ourense, Spain, ⁴⁵Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain, ⁴⁶Hospital La Mancha Centro, Alcázar de San Juan, Alcázar de San Juan, Spain, ⁴⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁴⁸Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Autoimmune diseases (AD) are complex diseases associated with both genetic and environmental risk factors. In the last 10 years major advances have been made…
Abstract Number: 826 • 2019 ACR/ARP Annual Meeting
Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
Meifang Wu¹, Eric Yen ² and Ram Raj Singh ², ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA, Los Angeles
Background/Purpose: Almost every organ system can be affected by primary immune-mediated diseases characterized by inflammation and therapeutic response to immune-suppressive or anti-inflammatory drugs. These diseases…
Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 880 • 2019 ACR/ARP Annual Meeting
Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development
Matthew Woodruff¹, Christopher Tipton ¹, Jennifer Hom ¹ and Iñaki Sanz ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Lupus nephritis (LN) is an autoimmune destruction of the kidney glomeruli and loss of kidney function affecting almost half of lupus patients. Although the…
Abstract Number: 2150 • 2019 ACR/ARP Annual Meeting
Frequency of Polyautoimmunity in a Tertiary Hospital
Elena Grau García¹, José Ivorra Cortés ¹, Jorge Juan Fragio Gil ¹, Roxana Gonzalez Mazarío ¹, Marta de la Rubia Navarro ¹, Cristóbal Pavez Perales ¹, Cristina Alcañiz Escandell ¹, Inmaculada Chalmeta Verdejo ¹, Luis González Puig ¹, Isabel Martínez Cordellat ¹, Rosa Negueroles Albuixech ¹, José Eloy Oller Rodríguez ², Francisco Miguel Ortiz-Sanjuán ¹, Elvira Vicens Bernabeu ¹, Carmen Nájera Herranz ¹, Inés Cánovas Olmos ¹, Samuel Leal Rodriguez ¹ and José Andrés Román Ivorra ¹, ¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain
Background/Purpose: Polyautoimmunity (PAI) is the presence of more than one Autoimmune Disease (AID) in one patient. PAI have been reported in different AIDs as systemic…
Abstract Number: 1076 • 2019 ACR/ARP Annual Meeting
Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases
Christina Chambers¹, Yunjun Luo ², Diana L. Johnson ², Kenneth Lyons Jones ² and Ronghui Xu ², ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla
Background/Purpose: In infants whose mothers were treated with biologic therapies during pregnancy, there has been a theoretical concern regarding potential risk of infections. Several recent…
Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Sara Remuzgo-Martínez¹, Diana Prieto-Peña ², Mónica Calderón-Goercke ², Victor Manuel Mora Cuesta ³, David Iturbe Fernández ¹, Sonia M. Fernández Rozas ³, Jose Manuel Cifrian Martínez ³ and Miguel Angel González-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
Abstract Number: 1077 • 2019 ACR/ARP Annual Meeting
Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications
Christina Chambers¹, Gretchen Bandoli ², Namrata Singh ³, Jennifer Strouse ⁴, Rebecca Baer ⁵, Brittney Donovan ⁶, Sky Feuer ⁷, Nichole Nidey ⁶, Kelli Ryckman ⁶ and Laura Jelliffe-Pawlowski ⁷, ¹University of California San Diego, La Jolla, ²University of California, San Diego, La Jolla, ³University of Iowa, Iowa City, ⁴University of Iowa Hospitals and Clinics, Iowa City, ⁵UCSD, La Jolla, ⁶UIOWA, Iowa City, ⁷UCSF, San Francisco
Background/Purpose: Autoimmune conditions are associated with an increased risk of adverse pregnancy complications and outcomes, suggesting that pregnancy complications may mediate the excess risk. We…
Abstract Number: 2296 • 2019 ACR/ARP Annual Meeting
Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease
Elisa Trujillo¹ and Erika Padrón ¹, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Women with chronic inflammatory and autoimmune diseases increasingly solicit assisted reproductive techniques (ART) due to infertility, but there is little information about success rates…
Abstract Number: 1270 • 2019 ACR/ARP Annual Meeting
Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study
Martin Michaud¹, Thomas Sene ², Pascal Chazerain ², Geoffrey Urbanski ³, Frederique Retornaz ⁴, Boris Bienvenu ⁵, Laurent Chiche ⁴, Florian Catros ⁶, Laurent Sailler ⁷, Laurent Alric ⁸, Jean Thomas Giraud ⁹, Léo Caudrelier ¹⁰, Slim Lassoued ¹⁰, Sophie Ancellin ⁶, Olivier Lidove ² and Francis Gaches ⁶, ¹Joseph Ducuing Hospital, Toulouse, France, ²Hôpital Croix Saint Simon, Paris, France, ³CHU Angers, Angers, France, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Saint Joseph, Marseille, France, ⁶Hôpital Joseph Ducuing, Toulouse, France, ⁷University Hospital of Toulouse, Toulouse, France, ⁸CHU Toulouse, Toulouse, France, ⁹Hôpital de Tarbes, Tarbes, France, ¹⁰Hôpital de Cahors, Cahors, France
Background/Purpose: There is increasing evidence of Tocilizumab (TCZ) efficacy in refractory auto-immune diseases. The present study aimed at evaluating the real-world experience of using TCZ…
Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting
Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Goh Murayama¹, Asako Chiba ², Tomohiro Mizuno ³, Atsushi Nomura ², Taiga Kuga ⁴, HIrofumi Amano ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting
Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Lauren Pachman¹, Wil Marin ², Gabrielle Morgan ¹, Megan L. Curran ³, Kaveh Ardalan ⁴, Chiang-Ching Huang ⁵ and Eli Roberson ⁶, ¹Northwestern University, Chicago, ²Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL, ³University of Colorado, Aurora, CO, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵University of Milwaukee, Milwaukee, WI, ⁶Washington University at St.Louis, St.Louis, MO
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood. Collaboration with A.R. French, MD/PhD, documented the…
Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Fan Zhang¹, Joseph Mears ¹, ilya Korsunsky ¹, Kevin Wei ², Anna Helena Jonsson ², Deepak Rao ¹, Edy Kim ³, Laura Donlin ⁴, Jill Buyon ⁵, Michelle Petri ⁶, Chaim Putterman ⁷, Thomas Tuschl ⁸, Nir Hacohen ⁹, Betty Diamond ¹⁰, Michael Brenner ¹¹ and Soumya Raychaudhuri ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boton, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Albert Einstein College of Medicine, New York, NY, ⁸Rockefeller Research Laboratories, New York, ⁹Broad Institute, Cambridge, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹Brigham and Women’s Hospital:, Boston
Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].